Literature DB >> 30213688

An epigenetic perspective on tumorigenesis: Loss of cell identity, enhancer switching, and NamiRNA network.

Ying Liang1, Peng Xu1, Qingping Zou1, Huaibing Luo1, Wenqiang Yu2.   

Abstract

Various tumorigenic theories have been proposed in the past century, which contribute to the prevention and treatment of cancer clinically. However, the underlying mechanisms of the initiation of cancer, drug resistance, neoplasm relapse, and metastasis are still challenging to be panoramically addressed. Based on the abundant evidence provided by others and us, we postulate that Tumor Initiated by Loss of Cell Identity (LOCI), which is an inevitable initiating event of tumorigenesis. As a result, normal cells are transformed into the cancerous cell. In this process, epigenetic regulatory program, especially NamiRNA (Nuclear activating miRNA)-enhancer-gene activation network, is vital for the cell identity. The disorganization of NamiRNA-enhancer-gene activation network is a causal predisposition to the cell identity loss, and the altered cell identity is stabilized by genetic variations of the NamiRNA-enhancer-gene activation network. Furthermore, the additional genetic or epigenetic abnormities confer those cells to carcinogenic characteristics, such as growth advantage over normal cells, and finally yield cancer. In this review, we literally explain our tumor initiation hypothesis based on the corresponding evidence, which will not only help to refresh our understanding of tumorigenesis but also bring benefits to developing "cell identity reversing" based therapies.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Enhancer; Loss of cell identity (LOCI); NamiRNA–enhancer–gene activation network; Tumor initiation

Mesh:

Substances:

Year:  2018        PMID: 30213688     DOI: 10.1016/j.semcancer.2018.09.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  4 in total

1.  Evidence for accelerated aging in mammary epithelia of women carrying germline BRCA1 or BRCA2 mutations.

Authors:  Sundus F Shalabi; Masaru Miyano; Rosalyn W Sayaman; Jennifer C Lopez; Tiina A Jokela; Michael E Todhunter; Stefan Hinz; James C Garbe; Martha R Stampfer; Kai Kessenbrock; Victoria E Seewaldt; Mark A LaBarge
Journal:  Nat Aging       Date:  2021-09-14

2.  Variation in the co-expression profile highlights a loss of miRNA-mRNA regulation in multiple cancer types.

Authors:  Gerardo Pepe; Luca Parca; Lorenzo Viviani; Gabriele Ausiello; Manuela Helmer-Citterich
Journal:  Noncoding RNA Res       Date:  2022-03-19

3.  Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy.

Authors:  Marcin Opławski; Agata Średnicka; Ewa Niewiadomska; Dariusz Boroń; Piotr Januszyk; Beniamin Oskar Grabarek
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

4.  FBP1 /miR-24-1/enhancer axis activation blocks renal cell carcinoma progression via Warburg effect.

Authors:  Dongen Ju; Ying Liang; Guangdong Hou; Wanxiang Zheng; Geng Zhang; Xinlong Dun; Di Wei; Fei Yan; Lei Zhang; Dong Lai; Jiarui Yuan; Yu Zheng; Fuli Wang; Ping Meng; Yong Wang; Wenqiang Yu; Jianlin Yuan
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.